Melanoma Research Institute of Excellence
Contact
Name:
Mitchell Berkowitz
Position:
Program Manager
Organization:
Melanoma Research Institute of Excellence
Contact Number(s):
Contact
Name:
Shingo Sato
Position:
- Associate Program Manager
- Director of Database Design and Utilization
Organization:
Melanoma Research Institute of Excellence
Email:
Shingo.Sato@jefferson.edu
Contact Number(s):
Clinical Trials
Marlana Orloff, MD
Principal Investigator
Takami Sato, MD, PhD
Principal Investigator
| A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
| A Study for the In Vitro Detection and Analysis of Circulating Biomarkers in Melanoma Patients from a Blood Draw |
Carin Gonsalves, MD
Principal Investigator
Rino Seedor, MD
Principal Investigator
| A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors |
| A Phase II Trial of Defactinib (VS-6063) Combined with VS-6766 (CH5126766) in Patients with Metastatic Uveal Melanoma |
| A Phase II Study of Concurrent Stereotactic Body Radiotherapy with Relatlimab and Nivolumab in Patients with Metastatic Uveal Melanoma |
| A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma |
| Geospatial Distribution of Uveal Melanoma |
| Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma |
| A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients with Resected Mucosal Melanoma |
| A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with PreviouslyUntreated Metastatic or Unresectable Melanoma; RELATIVITY-127 |
| A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop) |
| A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
Clinical Research Staff